Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Imatinib. Novartis.

Ian R Radford¹

¹Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia. i.radford@pmci.unimelb.edu.au

Current Opinion in Investigational Drugs (London, England : 2000)

|June 11, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Protection by methylproamine of irradiated human keratinocytes correlates with reduction of DNA damage.

International journal of radiation biology·2010

Same author

Clustered DNA lesion sites as a source of mutations during human colorectal tumourigenesis.

Mutation research·2008

Same author

Uncoupling of telomere length and radiosensitivity in mouse lymphoma cell lines of similar genetic background.

International journal of radiation biology·2007

Same author

Ionizing radiation-induced chromosomal rearrangements occur in transcriptionally active regions of the genome.

International journal of radiation biology·2005

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Novartis

Area of Science:

Oncology
Pharmacology
Molecular Biology

Background:

Chronic myeloid leukemia (CML) is a cancer driven by tyrosine kinases like Bcr-Abl.
Imatinib is a novel tyrosine kinase inhibitor developed for targeted cancer therapy.
Existing treatments for CML include interferon-alpha (IFNalpha), with limitations.

Purpose of the Study:

To evaluate imatinib as a treatment for chronic myeloid leukemia (CML).
To assess the efficacy of imatinib against other cancers expressing specific tyrosine kinases.
To investigate the mechanism of action of imatinib, including its effect on apoptosis.

Main Methods:

In vitro studies assessing imatinib's inhibition of Bcr-Abl and c-KIT tyrosine kinases.
Clinical trials investigating imatinib for CML and other malignancies.

Related Experiment Videos

Comparative analysis with existing therapies like IFNalpha.

Main Results:

Imatinib selectively inhibits Bcr-Abl and c-KIT tyrosine kinases, including constitutively active forms.
A strong correlation was observed between in vitro responses to IFNalpha and imatinib.
Imatinib induces apoptosis in Bcr-Abl-expressing cells and demonstrates potential for treating various cancers.

Conclusions:

Imatinib represents a promising oral alternative to IFNalpha for chronic-phase CML.
The drug's targeted mechanism and efficacy extend to other hematologic and solid tumors.
Imatinib's development signifies a significant advancement in targeted cancer therapy.